A rise in tuberculosis cases in Malaysia triggered social media posts falsely claiming that the bacteria responsible for the disease were deliberately inserted into Pfizer's Comirnaty Covid-19 vaccine ...

Hernexeos underwent an ultra-rapid 44-day regulatory review due to its inclusion in the FDA Commissioner's National Priority Voucher pilot program.

Boehringer’s lung cancer medicine Hernexeos is the second “national priority” voucher winner to gain a speedy approval. Elsewhere, a landmark gene therapy was withdrawn and a Pfizer deal paid ...

Government response The Global Impact of the COVID-19 Pandemic: A Comprehensive Overview The COVID-19 pandemic has undeniably ...

A patient has died in a mid-stage study of MacroGenics’ bispecific antibody lorigerlimab in gynecologic cancers, prompting ...

Source: Govt, Pfizer sign landmark health equity Accord – herald Trust Freddy Herald Correspondent GOVERNMENT has formally ...

Pfizer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Hympavzi hemophilia drug for two patient populations with significant medical need ...

Pfizer has received FDA priority review for a supplemental biologics license application to expand the indication of Hympavzi (marstacimab). The proposed label expansion would include patients with ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief executive officer saying he would consider a deal with a partner that gets ...

It's entirely possible that Pfizer stock will indeed rebound this year. Perhaps the most likely reason for a bounce is the potential for positive clinical results that excite investors. Many will ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual property developed by Monsanto, the crop science company the German company ...